Maite Bourlon @BourlonMaite Twitter profile

Pinned Tweet

Maite Bourlon

1 year

A Potpourri of options in 1L metastatic urothelial carcinoma. Are we ready to select??? Thanks @ASCO for inviting me 👩🏻‍⚕️🇲🇽🏨! @ConquerCancerFd @OncoAlert Thanks to the supportive GU cancers community @apolo_andrea @TomFlaigMD @DrChoueiri @montypal @tompowles1 @Ecastromarcos

5

28

115

Last Seen Profiles

@IsiChristi

@nclementracing

@johanne22337673

@hachi_duchi

@gunnar_18

@pomum_nail

@Wingedflow

@stwmaniax

@shopgld

@AmyDoerring

@StalkingVi96051

@OlivierParent15

@Bolly__wood

@AAthuraliy66458

@thedeadler

@somnium_sdc

@JasonStath47581

@FultonBBall

@bamzhik

@IhKitti

@Tatsukari

@mikecooln1

@bk_7700

@BinorRaja

@erotikfuneral

@show_ism

@s_khan1669

@MjjjjjM0

@dorazi0_0

@Piacluo044

@shiny_latex

@cdi_labs

@Ealasaid_MacD

@galery_basah10

@sshyvmv

@BdalkrymTy37107

Maite Bourlon

@BourlonMaite

2 years

A very happy day & a privilege to receive @ASCO @ConquerCancerFd 2023 International Women Who Conquer Cancer Mentorship Award!! 👩🏻‍⚕️🇲🇽👩🏻‍🔬🎉 Thanks @TomFlaigMD @DrJoseSifuentes @DKershenobich @Yuly_Remo @NayeliMartinezi @incmnszmx

32

36

251

Maite Bourlon

@BourlonMaite

4 years

We are so happy ! It was a team effort @DrChoueiri @Yuly_Remo @aminnsz @uroinnsz @incmnszmx @hugovesu @Bren_JF @profevasegelov Happy for our patients and our Clinic #Mexico #kidneycancer

Toni Choueiri, MD

@DrChoueiri

4 years

@drvmoyervides @BourlonMaite @CUCCUANL @fmuanl Dr. Bourlon played an important role in #9ER ! Glad to have her part of this effort @BourlonMaite cc: @CUCCUANL @EnriqueSoto8

1

2

24

28

18

238

Maite Bourlon

@BourlonMaite

2 years

So honored for the invitation to moderate @ASCO #ASCO22 kidney and bladder poster discussion! 👩🏻‍⚕️🇲🇽Thanks team @NehaVapiwala @crisuarez08 @DrChoueiri @tompowles1 @MattGalsky @anilkapoormd @shilpaonc @OncoAlert @urotoday @OncoReporte

20

24

233

Maite Bourlon

@BourlonMaite

2 years

iPARPs in HRR negative population read our article!!! 👩🏻‍⚕️👨‍⚕️👩🏻‍⚕️ @ASCO #ASCOGU23 🇲🇽🇺🇸🇪🇸 PARPi in Patients With HRR-Negative mCRPC: Why Would These Therapies Work in the Absence of a Mutation? 🔸DNA proficient tumor cells tx w iPARP with hormonal agents, radioligands & IO (figures)

5

46

156

Maite Bourlon

@BourlonMaite

9 months

Happy to present the CheckMate9ER study @ASCO #gu2024 👩🏻‍⚕️🇲🇽🦀 🔹 A P3 trial of cabo+nivolumab vs sunitinib in previously untreated advanced kidney cancer. 🔸@ 55m folow-up efficacy of the combo is maintained in OS, PFS and ORR 🔹Thanks for the great team and support! @URONCO

9

27

146

Maite Bourlon

@BourlonMaite

1 year

The @ASCO @ConquerCancerFd IDEA Program supports early career oncologists from LMIC’s. Congrats #ASCO2023 awardees! @relc_uroonco @DSG_MD @SergioContg @EdiBonci 👩🏼‍⚕️👨🏻‍⚕️🌍❤️ 10 years ago I was a recipient & now happy to be 2023-24 Chair 🧑🏻‍🎓🇲🇽

13

12

142

Maite Bourlon

@BourlonMaite

1 year

Very happy for the recognition!!! So happy to work in a Oncology 🇲🇽🌍💙🏨👩🏻‍⚕️ @oncodaily @OncoAlert @INCMNSZ_Uronco @incmnszmx

OncoDaily

@oncodaily

1 year

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023 🇺🇸🇯🇴🇨🇦🇳🇬🇮🇳🇧🇷🇲🇽🇦🇺🇬🇧🇳🇱 Today is Women’s Equality Day, celebrating the 1920 law that granted U.S. women the right to vote. Initiated in 1971 and made official in 1973,

16

35

115

10

7

133

Maite Bourlon

@BourlonMaite

1 year

📢 BMS @bmsnews Press release on CheckMate-67T study of subcutaneous Nivolumab while @myESMO begins 🔹P3 trial of SC Nivo vs IV Nivo 🔸Meets co-primary endpoints of Pharmacokinetics 👩🏻‍🔬 🔹Meets non-inferiority in ORR (secondary endpoint) Great team @AlbigesL @INCMNSZ_Uronco

2

42

107

Maite Bourlon

@BourlonMaite

1 year

Happy collaborator: WOMEN, POWER & CANCER @TheLancet Commission Lead by @OphiraG & great team @NarjustFlorezMD @dmukherji @EnriqueSoto8 🔸Cancer one of top 3 causes of premature death 🌍 🔹Gender transformative policies needed👩🏻‍⚕️ 🔸Risk fx: Tobacco alcohol obesity & infections

2

17

103

Maite Bourlon

@BourlonMaite

1 year

Thanks @ConquerCancerFd & @ASCO for the continuous support!!

Conquer Cancer, the ASCO Foundation

@ConquerCancerFd

1 year

@BourlonMaite is devoted to professional development of female colleagues as clinicians, educators, and researchers in oncology. Learn more about her and why she's a 2023 International Women Who Conquer Cancer Mentorship Award recipient: @incmnszmx

2

7

30

8

9

100

Maite Bourlon

@BourlonMaite

2 years

Thanks @ASCO for the opportunity! 🇲🇽👩🏻‍⚕️ 💙 Best of journals in Medical Oncology for RCC #kidneycancer @IKCCorg 🔸Triple therapy in mRCC 🔹TKI & IO cabo+nivo one of the highest responses in non-clear cell 🔸Pembro continues to have DFS. Atezolizumab & Ipi/Nivo no DFS or OS

6

26

101

Maite Bourlon

@BourlonMaite

1 year

Excited to be an #ASCO23 Featured Voice!! 👩🏻‍⚕️🇲🇽🏥🌍 I will be tweeting about: 🔸Urologic Oncology treatments in #kidneycancer #prostatecancer #bladdercancer #testicular cancer 🔸Global Oncology news @JCOGO_ASCO 🔸Awards and Special Events 🎉 @ConquerCancerFd

ASCO

@ASCO

1 year

📣 Announcing the #ASCO23 Featured Voices! 🎉 Follow on Twitter, Instagram and/or LinkedIn for a range of expert insights and join the conversation using the official hashtag: #ASCO23 👉

6

71

246

6

99

Maite Bourlon

@BourlonMaite

1 year

Enjoying the GU kidney and Bladder poster walk at #ASCO2023 !! @ASCO Thanks for the opportunity to guide this group @SalvadorjcMD @mauricemora9 @FersRivera 📍🏃🏻‍♀️🏃🏻🏃🏻‍♀️🏃🏻 We encountered wonderful poster presenters @NazliDizman @LuisMezaco @montypal 👩🏻‍⚕️👨🏻‍⚕️🎉✅

3

14

96

Maite Bourlon

@BourlonMaite

1 year

Mentorship & Career roundtable @ASCO #ASCO2023 @ConquerCancerFd chaired past-President Lori J Pierce 📍Carmen Guerra ⚖️ Equity 📍David Gerson 👨🏻‍⚕️Teaching 📍Patrick Loehrer 👨‍🎓Humanitarian 📍Jane Perlmutter 🏃🏻‍♀️Advocacy 📍Carolyn Runowicz 👩🏼‍⚕️WWCC 📍Maria T Bourlon👩🏻‍🔬International

7

11

93

Maite Bourlon

@BourlonMaite

9 months

Great to see you!! @ASCO #ascogu

Ana García

@ayahuasca21

9 months

Latinas en networking de Cáncer genitourinario @BourlonMaite @LauBernalOnc @nataliagandur #ASCOGU

0

4

30

3

6

88

Maite Bourlon

@BourlonMaite

4 years

Very happy to see our clinic participating ! @incmnszmx @HemOncINCMNSZ @mexico in 9er cabo Nivo in kidney cancer. Thanks to my team @Yuly_Remo @Bren_JF @hugovesu fco bruno Saldivar #ESMO2020 #gucancer

3

9

87

Maite Bourlon

@BourlonMaite

2 years

Great LATAM #GUcancer #ProstateCancer #bladdercancer meeting!!! @EfstathiouEleni 🇬🇷🇺🇸(🍀my fairy godmother) @Ecastromarcos 🇪🇸 @AL3X4M @DrFRodriguezCov 🇲🇽 @raymanneh 🇨🇴 @FabioSchutz78 🇧🇷 @aminnsz @uroinnsz @OncoAlert

2

14

87

Maite Bourlon

@BourlonMaite

2 years

#oncofertility in twitter! 🔹 Mostly from high income countries🌎 🔹Tweets are from physicians & healthcare centers, none from patients 👩🏻‍⚕️👨🏻‍⚕️ 🔹14.5% about children & adolescents 🔹Need strategies to ⬆️ content & awareness in social media @NayeliMartinezi

3

22

87

Maite Bourlon

@BourlonMaite

2 years

Are We Ready for Combination Immune Checkpoint and Tyrosine Kinase Inhibitor–Based Therapies for Metastatic Non–Clear Cell RCC? #ASCODailyNews @ASCO 🔸Getting ready #ASCOGU2023 🔸Thanks @drenriquegrande @NayeliMartinezi @Yuly_Remo @incmnszmx

1

25

85

Maite Bourlon

@BourlonMaite

9 months

Great! “PARPi for prostate cancer” 🔹1st targeted therapy for advanced disease ✅ TRITON-3 & PROFOUND showed benefit in mCRPC w DDR alt ‼️PROPEL, TALAPRO-2 & MAGNITUDE in 1L mCRPC but mostly unexposed to ARSi Is PARPi rechallenge possible? @Ecastromarcos @PaolaVS94 👩🏻‍⚕️🇲🇽🇪🇸

Elena Castro

@Ecastromarcos

9 months

Happy to share our review on the development of PARPi for prostate cancer, by @BourlonMaite at @TAMedOncol

0

10

44

1

30

85

Maite Bourlon

@BourlonMaite

7 months

@COI_salud @fundacion_coi Thanks for the aknowledgement: “Contribution for the development of Oncology in México” 2024 Thanks to my family! @chrisbourlon @INCMNSZ_Uronco @INCMNSZ_Ensena @aminnsz @incmnszmx

9

7

85

Maite Bourlon

@BourlonMaite

9 months

@ASCO Daily News Proposed algorithm! Adjuvant pembrolizumab is SOC for high-risk resected RCC 🔹Oligometastatic recurrence▶️ surveillance, surgery, radiation or ablative strategies 🔸Multifocal disease: refractory, early recurrence or late recurrence. ✅Treat accordingly

ASCO

@ASCO

9 months

Adjuvant pembro is rapidly becoming a new standard of care for resected #RCC , but how will we treat patients upon metastatic recurrence? @BourlonMaite @DrChoueiri #kcsm

2

22

38

1

35

81

Maite Bourlon

@BourlonMaite

1 year

Happy to be on board!! 👩🏻‍🔬🏨⛴️ @oncodaily !!!

OncoDaily

@oncodaily

1 year

Prominent Editorial Board Members of ! We are proud to have such esteemed experts and world-renowned oncologists shaping our work.

0

2

13

6

3

75

Maite Bourlon

@BourlonMaite

4 years

!! @JGO_ASCO reaches most of world’s economies @ASCO #ASCO20 . #GlobalOncology community needs to work on more LMICs collaboration & LICs authorship @ConquerCancerFd @GlopesMd @profevasegelov @OphiraG @Charbel_matar1 @Bren_JF @school_latin @SMEOMX

2

20

75

Maite Bourlon

@BourlonMaite

5 years

A very happy day at #ASCO2019 #globaloncology ! For sure a day I will not forget!! Thanks for all that supported me, the Mexico’s team, the University of Colorado and my family @chrisbourlon !!! @school_latin @aminnsz @SMEOMX @JGO_ASCO @GlopesMd

8

13

74

Maite Bourlon

@BourlonMaite

2 years

Thanks so much @ConquerCancerFd @ASCO !!

Conquer Cancer, the ASCO Foundation

@ConquerCancerFd

2 years

As Women's History Month ends, we're recognizing 2023 Women Who Conquer Cancer Mentorship Awards recipients: Dr. Carolyn D. Runowicz and Dr. María Teresa Bourlon. Thank you for being leaders for women conquering cancer around the globe. @BourlonMaite

0

4

20

5

2

72

Maite Bourlon

@BourlonMaite

1 year

Great event!! 40 under 40 in cancer 🎉 Happy to be part of the Class of 2023!!

Gonzalo Recondo

@GRecondoMD

1 year

Congratulations Dr. @BourlonMaite for being an awardee of the #40under40 emerging leader in cancer!

2

3

36

2

71

Maite Bourlon

@BourlonMaite

2 years

So happy to chair the “Oral Abstracts Flash track” session #ASGCR23 @NCIResearchCtr @NCIGlobalHealth 🔸Self-collected samples for cervical cancer screening Africa & Asia🌍 🔹Smoking cessation campaings in HIV 🔸Novel electronic resources for cancer awareness🏥 Online Networking

8

10

70

Maite Bourlon

@BourlonMaite

1 year

@ConquerCancerFd Award reception! Always a day to remember! ❤️🎉👩🏻‍⚕️ #ASCO23 Women Who Conquer Cancer Mentorship Awards 👩🏼‍⚕️👩🏻‍⚕️ @incmnszmx @INCMNSZ_Ensena and @relc_uroonco @SergioContg @hafaydeefe IDEA and International Innovation Grant! Wonderful Job @aminnsz ! 🏨🌍

6

12

68

Maite Bourlon

@BourlonMaite

9 months

Thanks for the opportunity to update this results!!! @ASCO

ASCO

@ASCO

9 months

Breaking news from #GU24 : CheckMate-9ER and CheckMate-214 updates continue to show a benefit with checkpoint inhibitor–containing combinations over sunitinib for the 1L treatment of advanced RCC: #ASCODailyNews @BourlonMaite @MDAndersonNews

2

6

21

0

8

68

Maite Bourlon

@BourlonMaite

1 year

The urothelial cancer community cannot wait to see the data!!! 👨🏻‍⚕️👩🏻‍⚕️🌍 🔸For decades platinum-based chemo was the SOC in 1st line 📣 🔹ADCs + IO combinations were promising 🙏🏻 🔸Cant wait to see the data on EV+pembro and become a new SOC ✌🏻

Jonathan Rosenberg MD

@DrRosenbergMSK

1 year

EV302 abstract: EV/pembro improves OS to 31.5 months c/w 16.1 months for chemo. Looking forward to seeing the data but this is transformative for the field and will change the standard of care. @MSKCancerCenter @tompowles1 @BladderCancerUS @MattGalsky @apolo_andrea

4

62

202

0

12

65

Maite Bourlon

@BourlonMaite

5 years

So happy to see this article @ASCO @JGO_ASCO editorial fellow @GlopesMd @emiliemgunn @incmnszmx @SMEOMX The importance IDEA program!!! Dr. Bourlon reflects on a career shaped by ASCO support, international collaboration, and unexpected opportuni...

It All Started With an IDEA

Dr. Maria Teresa Bourlon reflects on a career shaped by ASCO support, international collaboration, and unexpected opportunities.

connection.asco.org

2

11

65

Maite Bourlon

@BourlonMaite

2 years

How do we approach #penilecancer in older adults? 👴🏼 🔸Older patients ⬇️ likely to receive surgery, chemo or RT 🔸 Primary surgery associated ⬆️ cancer specific survival 🔸Competing mortality risks important in OS @TomFlaigMD @SpiessPhilippe @simon_p_kim

2

16

60

Maite Bourlon

@BourlonMaite

9 months

Almost time for @asco #GU24 !!

Neeraj Agarwal, MD, FASCO

@neerajaiims

9 months

Ab #362 @ASCO #GU24 by @BourlonMaite 👉👉55 mos f/u of CheckMate 9ER ph3 mRCC #kidneycancer 👉continued benefit w/ Nivo+Cabo vs Sunitinib ➡️ mOS 43.9 vs 29.3 mos in int/poor risk pts👇 @drchoueiri @OncoAlert @urotoday @Uromigos @KidneyCancer @tompowles1

1

20

47

0

12

59

Maite Bourlon

@BourlonMaite

3 years

Global Oncology authorship and readership @JCOGO_ASCO . Who is generating #globaloncology data and interested on it! Thanks to @ConquerCancerFd Editorial Fellow, @GlopesMd @emiliemgunn @OphiraG @profevasegelov @chrisbourlon @Bren_JF @Charbel_matar1 @DrFrancas @jrgralow @incmnszmx

3

14

57

Maite Bourlon

@BourlonMaite

9 months

Just at #gu2024 @ASCO 🔹Keynote 564! Adjuvant pembrolizumab in resected high risk RCC has OS benefit! @DrChoueiri 🔸 @PBarataMD discussed the data & highlighted our ASCO Daily News of What to do in patients recurring after adjuvant pembrolizumab?

0

11

55

Maite Bourlon

@BourlonMaite

2 years

Gracias por su asistencia @LuisMezaco @montypal @JaviMolinaC @raymanneh 🇵🇪🇪🇸🇨🇴🇲🇽 #kidneycancer mejorando desenlaces!! @SMEOMX Sociedad Mexicana de Oncología 2022

N

@NayeliMartinezi

2 years

Mensaje final del debate “Actualizaciones de las opciones terapéuticas de CCRa en 1L” @BourlonMaite @SMEOMX #SMEO 1️⃣ IO/IO o IO/TKI: mejor estrategia de 1L 2️⃣ El uso de estos combos requiere personal capacitado para el manejo de toxicidad 3️⃣ Incluir al px en ensayos clínicos

0

2

18

5

9

53

Maite Bourlon

@BourlonMaite

2 years

Thanks @oncofertility for the invite to talk about implementing oncofertility programs in Mexico LMICs #OCPitt2022 It’s time for resource-stratified guidelines #globaloncology @incmnszmx @_MahmoudSalama Thanks team @NayeliMartinezi @estefaniamr2 @PAMVIRI @ReginaBarCar

5

7

53

Maite Bourlon

@BourlonMaite

5 years

Thanks to Drs Glode, Flaig, Lam & Kessler @ASCO @ConquerCancerFd @incmnszmx @aminnsz @JGO_ASCO @SMEOMX @AnschutzHemeOnc @emiliemgunn @GlopesMd for your support. And ASCO staff for sending me original copies🤗

ASCO

@ASCO

5 years

. @BourlonMaite reflects on a career shaped by ASCO support, international collaboration, and unexpected opportunities @ConquerCancerFd #ASCOconnection

1

4

21

0

6

53

Maite Bourlon

@BourlonMaite

1 year

Such a wonderful effort!!! 🚑🏨👩🏻‍⚕️👨🏻‍⚕️ Happy to be part of the team 🌍🇮🇹🇲🇽🇧🇷🇪🇸🇨🇴 @fsabino_onco @SoaresAndrey @drenriquegrande @JaviMolinaC @CPRT65 @raymanneh @oraziocaffo 📩 Real world data on combos in 1st line for advanced renal cell carcinoma

Francesco Massari

@fmassari79

1 year

It is an big honor to share another work of the ARON group. Fantastic collaboration. Huge team! @EurUrolOncol @DrIacovelli @drenriquegrande @CPRT65 @procopio_g @SoaresAndrey @DrIgnacioOrtego @fsabino_onco @vmollica7

2

11

31

7

51

Maite Bourlon

@BourlonMaite

1 year

Wonderful #LATAM GU Oncology meeting in Mexico 🇲🇽👩🏻‍⚕️👨🏻‍⚕️🇧🇷🇦🇷🇨🇴 @SoaresAndrey @Ecastromarcos @zapatalaguadomd @OncologyBio @RomanCarvajal Great organization @JanssenUSOncMed

Rodrigo Coutinho Mariano

@Ro_Mariano85

1 year

Brilliant discussion about controversies in mCSPC conducted by my friend Dr Maluf! Triplet x doublet treatment is still a very debatable point and a better selection of patients is an critical point to improve. Biomarkers are eagerly needed! Congrats for all panelists!

0

4

10

0

6

50

Maite Bourlon

@BourlonMaite

1 year

It is a really great opportunity for early career oncologists in LMICs 👩🏻‍⚕️👨🏻‍⚕️🌍🏨from @ASCO @ConquerCancerFd @JCOGO_ASCO @TomFlaigMD @Yuly_Remo @SergioContg @melladoorellana @relc_uroonco @yaninchavarri @Dra_CVillarreal @GevTamamyan @SanuLR @chrisbourlon

OncoDaily

@oncodaily

1 year

2013 IDEA awardee at ASCO Conquer Cancer, the ASCO Foundation, and now Chair of the program! - @BourlonMaite @ConquerCancerFd @relc_uroonco @SergioContg @ASCO #ASCO #ASCOConquerCancer #Cancer #IDEAAwardee #MaiteBourlon #OncoDaily #Oncology

0

3

19

0

9

49

Maite Bourlon

@BourlonMaite

2 years

Don’t miss: Coaching in Oncology @ Women’s Networking Center @asco #ASCO2022 @LatinxOncology @school_latin 👩🏻‍⚕️👩🏼‍⚕️👩🏽‍⚕️👩🏻‍⚕️👩🏿‍⚕️ I will coordinate the discussion of wonderful leaders @profevasegelov @IshwariaMD Jennifer Griggs 🎉🎉

2

12

48

Maite Bourlon

@BourlonMaite

2 years

#ESMO2022 Using molecular data impacts in #prostatecancer 👨🏻‍⚕️🧑🏼‍⚕️🌍🌎 🔸metastatic disease genomically heterogeneous, WGS ▶️distinct entities 🔸gBRCA2 mutations are prognostic 🔸Tumor profiling may not identify some germline mutations @Ecastromarcos @MartijnLolkema @mishabeltran

0

13

49

Maite Bourlon

@BourlonMaite

4 years

The importance if #oncofertility @aminnsz in low resource settings. Outcomes and Challenges of Reproductive Health in Hematopoietic Stem Cell Transplantation. congrats @chrisbourlon @AAcosta_MedMD @GuliasAlfonso @oncofertility

Outcomes and Challenges of Reproductive Health in Hematopoietic Stem Cell Transplantation Survivors...

Long-term therapy-related reproductive health side effects impact the quality of life of hematopoietic stem cell transplantation (HSCT) survivors. In this study, we evaluated the prevalence of...

pubmed.ncbi.nlm.nih.gov

2

8

48

Maite Bourlon

@BourlonMaite

2 years

Wonderful summary of the #ASCRS22 @NCIGlobalHealth 10th Annual Symposium on Global Cancer Research! Glad to be @ASCO @JCOGO_ASCO representative in the planning of the event! Thanks @MishkaKohliCira @kalinaduncan #globaloncology @jrgralow

1

11

45

Maite Bourlon

@BourlonMaite

8 months

Great systematic review and Network Meta-Analysis for 1st line combinarions in metastatic urothelial carcinoma 👩🏻‍⚕️👨🏻‍⚕️🌍🦀

Fernando Sabino, MD, PhD

@fsabino_onco

8 months

⚡️Just out at @CHematology the 1st systematic review and NMA with immune-combos in 1st line mUC (including the data of EV-302 just published). @SoaresAndrey @fmassari79 @vmollica7 @BourlonMaite @shilpaonc @asasse @andrepcdc

4

5

28

2

3

47

Maite Bourlon

@BourlonMaite

1 year

Thanks for being wonderful mentees!! For your hard work on the difficult days and for sharing with me this @asco #ASCO2023 🇲🇽👨🏻‍⚕️👩🏻‍⚕️🏩🏨🏥🎉💙 @ConquerCancerFd @NayeliMartinezi @INCMNSZ_Ensena @medicinterna @aminnsz

Salvador Jaime-Casas, MD

@SalvadorjcMD

1 year

Huge congratulations to @BourlonMaite for all her #ASCO2023 awards. Recipient of both #40under40 and #conquercancer awards, she is truly and inspiring mentor for physicians worldwide. Could not think of a better person for these awards!!

1

3

22

1

3

47

Maite Bourlon

@BourlonMaite

4 years

What happens with older adults #gerionc with #penilecancer ? See our @myESMO #esmo2020 e-poster. Thanks @CUDenver Dr Flaig @ascotwit @hafaydeefe

2

15

45

Maite Bourlon

@BourlonMaite

1 year

Glad you like the discussion! The Bladder Cancer field is moving forward!! I am very thankful for the invitation @ASCO #ASCO2023 🇲🇽🌍👩🏻‍⚕️💙

Sumanta K. Pal, MD, FASCO

@montypal

1 year

Mesmerized by all the elegant discussions today. First @neerajaiims , then @anis_a_hamid , then @BraunMDPhD & now @BourlonMaite ! Dr. Bourlon offers a clear and concise distillation of trials from @drenriquegrande , #DrSiefkerRadtke & @shilpaonc . So excited to have her mentee,

1

22

67

5

45

Maite Bourlon

@BourlonMaite

2 years

Uncovering the benefits of #coaching ! We need it as oncologists!! @ASCO #asco2022 Women’s Networking Center panel @profevasegelov @SoniSmithMD @LatinxOncology @incmnszmx @SMEOMX @ReginaBarCar @amtzcannon @Dra_CVillarreal @ancasa2000 @Yuly_Remo @school_latin @yaninchavarri

0

10

45

Maite Bourlon

@BourlonMaite

11 months

Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population 👩🏻‍⚕️🦀🇲🇽 - We need to work to improve patient outcomes 📣

Oscar Arrieta

@ogarrieta

11 months

Lack of access to innovative treatments dramatically affects survival. Greater access to immunotherapy treatment is necessary for patients with renal cell cancer. Great collaborative work of Mexican oncologists led by @BourlonMaite and Dra. Nora sobrevilla. Congratulations for

1

31

111

1

9

44

Maite Bourlon

@BourlonMaite

2 years

@incmnszmx @aminnsz Medical Oncology Team enjoying very happy Moments @asco #asco2022 @hafaydeefe @RobertodelaPea6 @ReginaBarCar @amtzcannon @melladoorellana @lilian_beas @Escorzza

4

2

44

Maite Bourlon

@BourlonMaite

2 years

Excellent Peruvian Medical Oncology meeting @PeruanaSpom 🇵🇪 Uro-Onc session 🔸Neo/adjuvant tx bladder by @richardetmarti5 🔹Intensification tx in prostate $ precision @cdanicas @raymanneh 🔸Combos in 1st line #kydneycancer by @BourlonMaite 🔹Fighting prostate cancer in LATAM

0

5

43

Maite Bourlon

@BourlonMaite

4 years

So happy to see our study of immunosenescrnce in #testicularcancer survivors comentes @urotoday @hugovesu @Bren_JF @Yuly_Remo @hafaydeefe @aminnsz

UroToday.com

@urotoday

4 years

Immunosenescence profile and expression of the aging biomarker (p16INK4a) in #TesticularCancer survivors treated with chemotherapy. #BeyondTheAbstract on UroToday > @BourlonMaite @BioMedCentral @incmnszmx

1

7

8

1

9

42

Maite Bourlon

@BourlonMaite

2 years

Wonderful discussion!! @OncologyBio we have huge LATAM challenges @DrAndreFay @SoaresAndrey @fsabino_onco 🌎👩🏻‍⚕️👨🏻‍⚕️

Andrey Soares

@SoaresAndrey

2 years

Starting #GU23 with an outstanding review about 1L treatment of #RCC and an interesting spoiller about what we’ll see at #GU23 about #RCC with @BourlonMaite during a @OncologyBio meeting

1

4

32

2

4

43

Maite Bourlon

@BourlonMaite

11 months

Great international collaboration!! 🇧🇷🇲🇽🇮🇹🇪🇸🌍Great to see Mexican representation @INCMNSZ_Uronco

Fernando Sabino, MD, PhD

@fsabino_onco

11 months

Just out! SII index as a prognostic tool for mRCC in the immune combos era. Thanks all ARON team for the support. @fmassari79 @drenriquegrande @BourlonMaite @DrAndreFay @CPRT65 @JaviMolinaC

2

3

23

3

10

43

Maite Bourlon

@BourlonMaite

2 years

Adjuvant therapy kidney & bladder cancer #ASCO22 @ASCO 🔹No OS benefit found, just DFS 🔸Need to define NED & disease progression in this studies 🔹Need utility scales & better prognostic scores 🔸Can patients solve this riddle? @DebMaskens @apolo_andrea @IKCCorg @OncoAlert

0

11

41

Maite Bourlon

@BourlonMaite

2 years

Gracias por estar en Uro-Onco!! 👩🏻‍⚕️🌍🇲🇽💙

N

@NayeliMartinezi

2 years

Uro-onco fue mi primer familia en el INCMNSZ. Siempre voy a estar muy agradecida con todos. Tienen un enorme lugar en mi corazón 💙✨

1

0

48

0

3

38

Maite Bourlon

@BourlonMaite

2 years

Managing challeging urinary cancers 👾🤛🏻 🔸RT & chemo appoach differs in small cell, squamous & adenocarcinoma #bladdercancer 🔸CNS mets #kidneycancer need individual approach (surgery, RT, TKI, IO) 🔸SBRT oligometastatic & inoperable Stage I @DrAndreFay @BradMcG04

0

10

37

Maite Bourlon

@BourlonMaite

4 years

Recommendations from the ASCO Academic Global Oncology Task Force. Thanks @ASCO @JGO_ASCO for advancing the Global Oncology field. An honor to participate in the taskforce. @GlopesMd @jrgralow @JuliaLClose @profevasegelov @ASCO_pubs

Recommendations from the ASCO Academic Global Oncology Task Force - PubMed

In recognition of the rising incidence and mortality of cancer in low- and middle-resource settings, as well as the increasingly international profile of its membership, ASCO has prioritized efforts...

pubmed.ncbi.nlm.nih.gov

0

10

36

Maite Bourlon

@BourlonMaite

5 years

Wonderful Prostate cancer discussion with @EfstathiouEleni @MDAndersonNews at @incmnszmx @aminnsz Thanks for coming to our meeting!

3

35

Maite Bourlon

@BourlonMaite

1 year

The therapeutic landacape of #bladdercancer has changed!! ✅ Patients w FGFR alterations can be treated w erdafitinib 👩🏻‍🔬🏨🧬 🔹Phosphorus needed for dose titration 🫙 🔹Skin, nails & 👁️ toxicity!!! 🔹High disease control rate @EvelynBeas2 @Yuly_Remo @DrFrancas @TomFlaigMD

CancerNetwork®

@CancerNetwrk

1 year

The June issue of ONCOLOGY is ready and available to download. This month we feature a urothelial carcinoma clinical quandary by @BourlonMaite and a kidney cancer review by Naveed Ahmed Mahar, MBBS. #oncology #medtwitter

0

4

0

14

35

Maite Bourlon

@BourlonMaite

4 years

So happy to share this podcast with my #globaloncology mentor @profevasegelov @ConquerCancerFd @ASCO @JGO_ASCO @GlopesMd

Craig Underhill

@CraigUnderhill

4 years

Congrats to the women who put this together @profevasegelov , Rachael Babin @OncologyNewsAus and @BourlonMaite in Mexico 🇲🇽 #Cancer #oncology #MedTwitter #MedEd

0

1

10

0

5

31

Maite Bourlon

@BourlonMaite

1 year

Very proud of @Yuly_Remo and @INCMNSZ_Uronco efforts in Mexican 🇲🇽👩🏻‍⚕️👨🏻‍⚕️🏨 #kidneycancer research

INCMNSZ_Uronco

@INCMNSZ_Uronco

1 year

Happy to see our @INCMNSZ_Uronco @incmnszmx representative @Yuly_Remo 🇲🇽👩🏻‍⚕️🇨🇴at the @IKCCorg meeting in receive the Scholarship Award 2023. Impact of Healthcare system in survival amont Mexican patients w #kidneycancer Thanks @EJonasch @StenioZequi @BourlonMaite @AleAsociacion

3

7

22

1

32

Maite Bourlon

@BourlonMaite

9 months

First SC inmmune chechpoint inhibitor in mRCC 🦀👨🏻‍⚕️👩🏻‍⚕️🌍

David Braun

@BraunMDPhD

9 months

Really nice work from Dr. Saby George @RoswellPark , with @AlbigesL @BourlonMaite and others, looking at subcutaneous nivo administration. Looks very similar to IV in terms of PK, efficacy, safety. Could really change how nivo is delivered in the future @ASCO #GU24

2

12

25

2

4

32

Maite Bourlon

@BourlonMaite

2 years

Bipolar Andrógeno Therapy for advanced #prostatecancer by @EfstathiouEleni #ASCOGU23 🔸Androgens revert androgen independence 🔹TRANSFORMER: phase II trial of BAT vs enzalutamide 🔸Offer germline and somatic testing!! Poot prognosis events in HRR 👩🏻‍🔬 🔹Always offer other options

0

7

32

Maite Bourlon

@BourlonMaite

4 years

Could not be posible with our the support of @ConquerCancerFd @ASCO @JGO_ASCO and out mentors Eva Segelov @OphiraG and @GlopesMd

Charbel Matar

@Charbel_matar1

4 years

Happy to share our abstract in the #ASCO2020 about #GlobalOncology authorship and access patterns. @BourlonMaite @OphiraG @GlopesMd @profevasegelov @ASCO @ASCO_pubs

2

27

0

2

30

Maite Bourlon

@BourlonMaite

4 years

My pleasure #GUREVIEW2020

Andrey Soares

@SoaresAndrey

4 years

Best of journal session: metastatic prostate cancer. Stellar presentation and discussion @BourlonMaite @jpsade2 @DrAndreFay @asasse @DrLages #GUREVIEW2020

1

5

15

1

2

30

Maite Bourlon

@BourlonMaite

2 years

UPDATED results of the CheckMate 9ER!! Improving outcomes in #KCSM @DrChoueiri @apolo_andrea @crisuarez08 @BurottoMauricio Great team effort!!!

Toni Choueiri, MD

@DrChoueiri

2 years

1/ CheckMate-9ER extended f/u (media f/u=32.9mo) results out in @TheLancetOncol : preplanned final OS analysis, updated PFS, OR & safety of Cabo/Nivo vs. Sun in 1L RCC. Also includes prespecified & post-hoc subgroup analyses. @OncoAlert @DanaFarber_GU

1

32

95

1

8

30

Maite Bourlon

@BourlonMaite

1 year

Thanks for you continuos support @TomFlaigMD !! Thanks for the feedback @apolo_andrea @tompowles1 👩🏻‍⚕️🇲🇽👨🏻‍⚕️🌍 It is a wonderful GU cancer community💙 Thanks for my team for the help with the slides @FersRivera @SalvadorjcMD @mauricemora9 @incmnszmx @aminnsz

Thomas Flaig

@TomFlaigMD

1 year

Outstanding discussion by @BourlonMaite at #ASCO2023 highlighting the developments in the treatment landscape for advanced cisplatin-ineligible urothelial carcinoma. Congrats!

1

9

31

0

7

28

Maite Bourlon

@BourlonMaite

3 years

Mentor and mentees avatar @NCIGlobalHealth 10th Annual Meeting on Global Cancer Research poster session. @ASCO representation #ASGCR @NayeliMartinezi @estefaniamr2 @MishkaKohliCira @jrgralow

4

3

26

Maite Bourlon

@BourlonMaite

2 years

Gracias a la @UPMexico por fomentar nuestro papel el la ciencia 👩🏻‍⚕️🌎👩🏻‍🔬🥽🏨🧠🫁🫀

Universidad Panamericana Ciudad de México

@UPMexico

2 years

La Dra. @BourlonMaite , alumni de @MedicinaUP deja claro que a través de la ciencia la mujer tiene un gran terreno conquistado en México. Aquí, lo nuevo de nuestro podcast, El Sonido de la Ciencia: #MujerYNi ñaEnLaCiencia #MujeresTransformandoElMundo

0

4

14

0

1

29

Maite Bourlon

@BourlonMaite

1 year

@SalvadorjcMD 👨🏻‍⚕️🇲🇽presenting our work #ASCOQLTY23 Inclusion of sex and gender instructions to author a and SAGUER guidelines recommendations across highest impact Oncology Journals 📢Most Oncology journals are not in compliance with guidance for sex and gender reporting

2

13

29

Maite Bourlon

@BourlonMaite

5 years

Wonderful meeting!! Thanks for the invitation @anelcabrera @asco @incmnszmx @incanMX to present the #globaloncology Educational session !!

Enrique Soto

@EnriqueSoto8

5 years

Had a great time presenting our #patientnavigation #supponc #pallonc #palliative research at the Best of @ASCO #asco19 in Cancún! Thanks @anelcabrera and @incanMX for inviting me! @yaninchavarri @BourlonMaite @incmnszmx @GeriatriaINNSZ

3

8

61

0

4

28

Maite Bourlon

@BourlonMaite

2 years

We had fun learning about #kidneycancer @drenriquegrande ! Thanks to our fellows for their enthusiasm @incmnszmx @HemOncINCMNSZ @incanMX @medicasur @AbigailMateos10 @ReginaBarCar @RosaCab23055941 Thanks #IPSEN for funding this CME event!

Raúl Mellado-Orellana

@melladoorellana

2 years

Today we had the opportunity to exchange views on renal cancer with @drenriquegrande and different residents from other cancer centers! @incanMX @medicasur @incmnszmx thank you! @BourlonMaite

0

4

38

2

26

Maite Bourlon

@BourlonMaite

9 months

Muy contentos de ver a @INCMNSZ_Uronco en este artículo de cáncer de prostata * Gracias @PaolaVS94 y @Ecastromarcos

Dirección de Investigación INCMNSZ

@INCMNSZ_DirInv

9 months

La presente muestra el desarrollo de PARPi en el cáncer de próstata, las sinergias y combinaciones que se están investigando, así como las direcciones futuras de PARPi .DOI. 10.1177/17588359231221337 Participación del @INCMNSZ , @BourlonMaite #Hemato -Oncología. @SMEOMX

0

1

5

1

4

28

Maite Bourlon

@BourlonMaite

9 months

We have a new standard of care in resected RCC! 👩🏻‍⚕️👨🏻‍⚕️✅🌍

Chris Labaki

@Chrislabaki1

9 months

Elegant discussion by @PBarataMD about adjuvant IO therapies in #RCC with an overview of outstanding work across different settings from colleagues @ZiadBakouny @RCCadvocate @BourlonMaite @ASCO @OncoAlert

2

4

15

0

2

27

Maite Bourlon

@BourlonMaite

5 years

#ASCO @JGO_ASCO @asco19 Editorial Fellows working in #globaloncology projects. @Charbel_matar1 @dmukherji @GlopesMd

0

4

27

Maite Bourlon

@BourlonMaite

5 years

Estamos felices!! Una iniciativa de @AsociacionAle @IKCCorg @aminnsz para incrementar el conocimiento de Cancer renal en México #kidneycancer #awarness Gracias a @DrFRodriguezCov @hafaydeefe @Yuly_Remo @nora18102267 @fjca7 @SMEOMX @smumexico

FEMETRE

@FEMETREAC1

5 years

La Dra. @BourlonMaite participará en el #ThinkTankCancerDeRi ñón, evento que nos permitirá aprender más sobre esta enfermedad #NecesitamosHablarSobreC áncerDeRiñón

0

6

9

1

9

27

Maite Bourlon

@BourlonMaite

5 years

Gracias por el apoyo! Reunion mas grande para pacientes con Cancer renal @M éxico. Biggest meeting for renal Cancer patients in Mexico. Thanks for the support! #kidneycancer @DrFRodriguezCov @StenioZequi @MichaelASJewett @IKCCorg @FEMETREAC1 @Yuly_Remo @hugovesu @hafaydeefe

2

6

28

Maite Bourlon

@BourlonMaite

2 years

It was a pleasure to see you @montypal !! Thanks for all your efforts in growing the Uro-Oncology community around the world!! @PauloBergerot @crisbergerot @LuisMezaco @Martin_AngelMD @fedelosco @DrChoueiri @tompowles1

Sumanta K. Pal, MD, FASCO

@montypal

2 years

Chance encounters at #ESMO22 were 1 of the best elements of the meeting. Whether coffee w @BourlonMaite to discuss a mentorship plan for @ReginaBarCar , wearing 😎 for no good reason w @YJanjigianMD or reflecting on the mtg w @TonyMok9 @herbloong @GIcancerDoc , it was awesome!

2

5

48

0

6

28

Maite Bourlon

@BourlonMaite

2 years

Wonderful time @SMEOMX 2022 #kidneycancer #bladdercancer 🔸IO/IO & IO/TKI combos are standard in first line in mRCC 🔸Metastatic urothelial carcinoma discussion on challenges of implementing maintenance IO 🔸Excellent RWD on mUC in 🇲🇽by 👩🏻‍⚕️👨🏻‍⚕️mentees @SJaimeC @RAlejandroOrtiz

0

6

27

Maite Bourlon

@BourlonMaite

5 years

Wonderful ASCO experience @ASCO @ASCO_pubs

ASCO

@ASCO

5 years

Five editorial fellows got an inside look at academic publishing during their @ASCO_Pubs editorial fellowships. @YAbdouMD @BourlonMaite @guptaarjun90 @EllenKimMD @Charbel_matar1 share their experience #ASCOconnection

0

10

34

0

2

27

Maite Bourlon

@BourlonMaite

3 years

How to assess muscle wasting in #ProstateCancer ?? @SciReports @NaturePortfolio @aminnsz @uroinnsz @incmnszmx @alanespinosam @castialon QoL is important @crisbergerot @Martin_AngelMD

2

3

27

Maite Bourlon

@BourlonMaite

2 years

We had a wonderful time !! @melladoorellana @lilian_beas @amtzcannon @ReginaBarCar @aminnsz @ancasa2000 @RobertodelaPea6 @yaninchavarri @hafaydeefe #ASCO2022 👩🏻‍⚕️🇲🇽👨🏻‍⚕️

Yanin Chávarri

@yaninchavarri

2 years

INCMNSZ family #ASCO2022 @ASCO @HemOncINCMNSZ @incmnszmx

0

3

46

0

4

25

Maite Bourlon

@BourlonMaite

10 months

Great team effort from Emerging Markets!! @SoaresAndrey @tompowles1 @raymanneh 🔹 #globaloncology perspective on the status of urothelial carcinoma in LMICs 🌍🦀👩🏻‍⚕️ 🚫Lack of cancer registries ▶️ insufficient data on incidence & mortality ‼️Diverse challenges in access to care

Andrey Soares

@SoaresAndrey

10 months

The tx of mUC has evolved in the last years, but it is still challenging in the #LIMC . In this review, the authors from different regions discuss the gaps, challenges and suggestions to improve mUC care in the #LMIC . @BourlonMaite @tompowles1 @raymanneh

1

4

15

0

5

25

Maite Bourlon

@BourlonMaite

2 years

Thanks to my @incmnszmx team @dralvaroaguayo @RobertodelaPea6 @Yuly_Remo @RosaCab23055941 @NayeliMartinezi @estefaniamr2 @melladoorellana @Escorzza @hafaydeefe and Latam friends supporting me @jpsade2 @Martin_AngelMD @FabioSchutz78 @SoaresAndrey and Spain @drenriquegrande

6

2

24

Maite Bourlon

@BourlonMaite

1 year

@ConquerCancerFd Awards ceremony @asco #ASCO23 🎉🎉 Thankful for the Wowwn Who Conquer Cancer Mentorship Award! 👩🏻‍⚕️🌍💙 Proud of IDEA recipients @SergioContg @relc_uroonco & IIG @hafaydeefe from @incmnszmx @INCMNSZ_Ensena 🏥🏨👩🏻‍⚕️👨🏻‍⚕️👩🏻‍⚕️🇲🇽

1

5

24

Maite Bourlon

@BourlonMaite

5 years

Definetely Latin American countries share similar #globaloncology problems @PauloBergerot

Paulo G Bergerot

@PauloBergerot

5 years

. #Globaloncology OUTSTANDING M.Bourlon comprehensively covered "universal" issues in #LMIC #oncology #education I’ve deeply identified from my experiences in #Brazil ➡️mentorship ➡️literature access ➡️priv vs public inst jobs ☑️ @ASCO initiatives: IDEA,Journal fellowship #ASCO19

0

12

34

0

6

24

Maite Bourlon

@BourlonMaite

2 years

find the link here!!

PARPi in Patients With HRR-Negative mCRPC: Why Would These Therapies Work in the Absence of a...

Compiling physiologic evidence of the synergistic effects of PARPi with ARPi, immunotherapy, or RLT is growing with early signals of their potential efficacy in clinical trials, including the use of...

dailynews.ascopubs.org

0

6

23

Maite Bourlon

@BourlonMaite

5 years

Thanks @ConquerCancerFd @asco

Conquer Cancer, the ASCO Foundation

@ConquerCancerFd

5 years

The International Development and Education Award connects #cancerresearchers from abroad with leading U.S. #oncologists . @BourlonMaite shares her story from IDEA recipient to @ASCO leader #ASCOconnection #WomenInMedicine #WomenWhoConquerCancer

0

4

9

0

2

23

Maite Bourlon

@BourlonMaite

3 years

Cabo/Nivo in mRCC according to baseline characterisrics!!

Andrea Apolo, M.D.

@apolo_andrea

3 years

Abstract 4553: Checkmate 9ER with CaboNivo in 1L #RenalCellCarcinoma outcomes by baseline characteristics (IMDC risk, Organ site of mets, # of organ sites with mets, sum of diameters of target lesions) PFS/ORR for all (and OS for most subgroups) favor CaboNivo @ASCO #ASCO21

3

29

60

0

5

22

Maite Bourlon

@BourlonMaite

6 years

The #ESMOSummit2019 ends. Wonderful experience!! Thanks to the @SBOC_Oncologia & @myESMO for the excelent organization. We will be waiting for you next year in Mexico. @SMEOMX

1

5

20

Maite Bourlon

@BourlonMaite

2 years

Thanks @Martin_AngelMD for your support!! 🇲🇽🇦🇷

Martín Angel

@Martin_AngelMD

2 years

Happy to see a #LATAM Oncologist discussing GU posters!. Great choice @ASCO chossing Dr. @BourlonMaite for this!! #ASCO22

0

5

54

0

1

20

Maite Bourlon

@BourlonMaite

4 years

Glad to see #bladdercancer treatment changes in @myESMO guidelines

ESMO - Eur. Oncology

@myESMO

4 years

New ESMO eUpdate: ESMO Clinical Practice Guidelines for #bladdercancer 👉 Maintenance avelumab is recommended in metastatic UC cancers which have not progressed on first-line platinum-based ChT (4-6 cycles) 👉 #blcsm @Annals_Oncology

0

28

39

0

10

19

Maite Bourlon

@BourlonMaite

4 years

Thanks to @oncofertility @ANZoncofert @woodrufflab for the support and the @JGO_ASCO @emiliemgunn @GlopesMd for highlighting the importance of oncofertility

Oncofertility

@oncofertility

4 years

New paper and a great read from @oncofertility global partners: Oncofertility as a Universal Right and a Global Oncology Priority @ANZoncofert @BourlonMaite

0

8

13

1

19

Maite Bourlon

@BourlonMaite

4 years

#AACRcovid @AACR see our GU Cánceres Clinic organization during the pandemia @aminnsz #telemedicine #globaloncology